greeksoup/ stock research
Stock research / United States / ACAD / Q4 FY2023

Acadia Pharmaceuticals (ACAD) Q4 FY2023 earnings: revenue $231 million, up 69.3% on the year

Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $231 million for Q4 FY2023, the quarter ended 31 December 2023, up 69.3% on the same quarter a year earlier. Net income was $46 million, and diluted earnings per share $0.28. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.

Revenue$231 millionup 69.3%
Net income$46 million
Diluted EPS$0.28
QuarterQ4 FY2023ended 31 December 2023

The quarter, against the one before and a year earlier

LineQ4 FY2023Q3 FY2023A year earlierChange on the year
Revenue231212n/an/a
Cost of revenue17.914.6n/an/a
Gross profit213197n/an/a
Gross margin92.3%93.1%n/a
Research and development66.7157n/an/a
Selling, general and administrative11197.9n/an/a
Operating income34.9-57.8n/an/a
Operating margin15.1%-27.3%n/a
Pre-tax income39.7-52.1n/an/a
Income tax-6.113.0n/an/a
Effective tax rate-15.3%n/an/a
Net income45.8-65.2n/an/a
Net margin19.8%-30.8%n/a
Diluted EPS$0.28-$0.40n/an/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2023Q3 FY2023A year earlierChange on the year
Operating cash flow85.4-59.0n/an/a
Cash from investing-0.334.1n/an/a
Cash from financing5.412.8n/an/a
Depreciation and amortisation1.61.7n/an/a
Share-based compensation18.018.5n/an/a
Diluted shares, weightedn/a164mn/an/a
Shares outstanding at period end165m164mn/an/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2023Q3 FY2023A year earlierChange on the year
Shareholders' equity432362n/an/a
Debt0.00.0n/an/a
Operating lease liabilities47.848.1n/an/a
Other liabilities269222n/an/a
Total liabilities and equity749633n/an/a
Fixed assets4.64.9n/an/a
Intangible assets65.566.9n/an/a
Investments250248n/an/a
Cash and equivalents18998.2n/an/a
Receivables98.392.8n/an/a
Inventory40.425.4n/an/a
Other assets10196.7n/an/a
Total assets749633n/an/a

Questions

What was Acadia Pharmaceuticals' revenue in Q4 FY2023?

Acadia Pharmaceuticals (ACAD) reported revenue of $231 million for Q4 FY2023, the quarter ended 31 December 2023, up 69.3% on the same quarter a year earlier.

How much did Acadia Pharmaceuticals earn in Q4 FY2023?

Net income for Q4 FY2023 was $46 million, and diluted earnings per share $0.28.

When did Acadia Pharmaceuticals report Q4 FY2023 results?

Acadia Pharmaceuticals filed its 10-K for the quarter ended 31 December 2023 with the SEC on 28 February 2024.

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue212231206242250260244265279284268308
Cost of revenue14.617.923.018.218.921.820.420.721.626.224.828.3
Gross profit197213183224232238224244257258243280
Gross margin93%92%89%92%92%92%92%92%92%91%91%91%
R&D15766.759.776.266.610178.378.087.884.876.981.6
SG&A97.9111108117133130126134133156171160
Operating income-57.834.915.230.431.615419.332.435.817.4-4.637.8
Operating margin-27%15%7%13%13%59%8%12%13%6%-2%12%
Pre-tax income-52.139.721.037.238.816127.840.244.626.34.046.5
Tax raten/a-15%21%10%16%11%32%34%-61%-939%9%32%
Net income-65.245.816.633.432.814419.026.771.82743.631.5
Net margin-31%20%8%14%13%55%8%10%26%96%1%10%
Diluted EPS-$0.40$0.28$0.10$0.20$0.20$0.86$0.11$0.16$0.42$1.60$0.02$0.18
Operating cash flow-59.085.429.125.063.240.420.364.074.3-48.734.0101
Capital expendituren/an/an/an/a0.1n/a0.00.30.44.05.25.1
Free cash flown/an/an/an/a63.2n/a20.363.773.9-52.728.895.7
Shares outstanding164m165m165m166m166m167m167m169m169m170m171m172m
Filing10-K10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2023, filed 28 February 2024, accession 0000950170-24-021473: the filing on EDGAR. All of Acadia Pharmaceuticals Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install